Document:

EX-10.14.1

 Exhibit 10.14.1 
 CONFIDENTIAL 
 LABORATORY SERVICES AGREEMENT 

This LABORATORY SERVICES AGREEMENT (hereinafter referred to as the “Agreement” is made by and between Biocept, Inc. (Biocept),
a California Corporation having its principal place of business at 5810 Nancy Ridge Drive, Suite 150, San Diego, CA 92121, and Clarient Diagnostic Services, Inc., a wholly owned subsidiary of Clarient, Inc., a Delaware corporation, having its
principal place of business at 31 Columbia, Aliso Viejo, CA, 92656 (hereinafter referred to as the “Clarient”). This Agreement replaces, as of the Effective Date, any former agreements or letters of intent that were previously signed by
both parties, including that certain Collaboration Agreement, as amended, by and between Biocept and Clarient dated as of August 17, 2011, which is hereby terminated as of the Effective Date, but excluding the letter agreement between the
parties dated December 5, 2012 regarding SOW#01 and the DFPCC Agreement, which shall continue. 
 WHEREAS, Biocept has
developed expertise and proprietary technology in enrichment, extraction and analysis of circulating tumor cells for use in diagnostic tests used for the non-invasive and early stage detection of metastatic or recurrent cancers; and 

WHEREAS, Clarient is in the business of providing anatomic and molecular pathology services in oncology to the medical community, the
pharmaceutical industry and other markets; 
 NOW, THEREFORE, it is the intent of both parties to proceed as follows: 

AGREEMENT 

In consideration of the mutual covenants, agreements, representations, warranties, and conditions contained herein, the Parties hereby
agree as follows: 
  

	1.	Definitions 

 1.1      “Assay” shall mean Biocept’s OncoCEE-BRTM assay which incorporates circulating tumor cell enumeration by cytokeratin (and
CEE-EnhancedTM when available and validated by Biocept), HER2 by fluorescence in situ hybridization, and any improvements or enhancements thereto, appropriately validated, exclusive of new analytes. 

1.2      “Parties” includes Biocept and Clarient, and “Party”
refers to either Biocept or Clarient. 
 1.3      “Sample” refers
to a medical sample to be tested with the Assay. 

1.4      “Term” shall be as specified in Section 2 of this Agreement.

  

	2.	Term of Agreement 

 2.1      The Effective Date of this Agreement is May 1, 2013. 
 2.2      This Agreement shall expire two (2) years (“End Date”) after the Effective Date unless the Parties agree in writing and prior to the End Date
to extend the Term of this Agreement. 

  

			
	Biocept Clarient Laboratory Services Agreement	 	Page 1 of 8

 CONFIDENTIAL 

 

2.3      The Term of this Agreement shall begin on the Effective Date
and shall end on the End Date, unless earlier terminated pursuant to the provisions of this Agreement. 
  

	3.	Biocept Services 

 3.1      Biocept agrees to provide Clarient with the necessary information and training to collect and send test requests for the Assay from its clients to
Biocept’s CLIA-certified, CAP-accredited laboratory in San Diego, CA per Biocept’s pre-determined specimen requirements. 
 3.2      Biocept’s laboratory and contracted medical staff shall perform both the Technical and Professional Components of the Assay. Biocept shall provide the
patient report directly to the ordering physician of Clarient’s client, with a copy sent to Clarient. 
  

	4.	Billing & Insurance 

 4.1      Biocept shall be solely responsible for billing the patient, the provider and/or the payer for the Assay, including both the Technical Component and the
Professional Component of the Assay, and the collection of such amounts with respect to each Assay performed. Biocept shall bill for such insurance according to the services provided by Biocept and per Biocept’s usual and customary third party
insurance billing policy using the appropriate CPT codes. Biocept shall bear all collection risk for reimbursement for the Assay; Clarient shall have neither billing nor collection responsibility and shall have no liability to Biocept for the
payment of Biocept’s performance of the Assay. 

4.2      At all times during the term of this Agreement, Biocept
shall maintain comprehensive professional liability insurance covering itself and its employees, contractors, and agents providing testing services pursuant to this Agreement. The insurance coverage maintained by Biocept shall be at least two
million dollars ($2,000,000) per occurrence and five million dollars ($5,000,000) in the annual aggregate. At Clarient’s request, Biocept shall provide Clarient with a certificate of insurance evidencing that such coverage is in effect during
the term of this Agreement. 
  

	5.	Regulatory Compliance 

 5.1      Compliance with Laws.    Biocept and Clarient and their respective Affiliates each agree to perform their respective obligations
under this Agreement in material compliance with applicable federal, state and local laws, rules, and regulations, including but not limited to applicable regulations, rules, and policies of third party payers that pay for the Assay. 

5.2      Privacy.    Biocept and Clarient and
their respective Affiliates agree to protect the privacy and provide for the security of any information that relates to a patient’s past, present, or future physical or mental health or condition in accordance with HIPAA, and any other
applicable federal and state privacy laws and regulations. Each party agrees to execute one or more Business Associate Agreements (as defined under HIPAA) as the other party, or its providers or payers, may from time to time request. 

5.3      Licenses and Certifications.    Biocept
shall have, at all times during the Term, all necessary federal, state and local licenses, qualifications and certifications to operate a laboratory and perform the components of the Assay, including, but not limited to, state laboratory licenses

  

			
	Biocept Clarient Laboratory Services Agreement	 	Page 2 of 8

 CONFIDENTIAL 

 
 
(excluding New York, Florida and Rhode Island; Biocept will notify Clarient when licenses in these states are obtained), CLIA certification, CAP (College of American Pathologists) certification,
and any other licenses or certification required by state and/or federal law. All Assays performed by Biocept shall be in accordance with applicable state and federal testing requirements for clinical reference laboratories. 

 

	6.	Termination 

 6.1      Either party may terminate this Agreement by providing the other party with a written termination notice, and such notice shall terminate this Agreement
(a) Sixty (60) days after the date of the notice, or (b) on the End Date, whichever is earlier. 
 6.2      Any termination or expiration of this Agreement shall be without prejudice to any other right or remedy that has accrued prior to the effective date of such
termination or expiration and/or that is afforded to the terminating party under any applicable law. Section 5.2 and Articles 7-10 shall survive termination or expiration of this Agreement. 

6.3      Either Party may immediately terminate this Agreement, by
providing written notice to the other Party upon the occurrence of any of the following three situations of this Subsection: 
 (a)      if the other Party materially breaches its obligations, warranties, or representations made in this Agreement if such breach continues for thirty (30) days
after receiving written notice thereof from the non-breaching Party; 

(b)      to the extent permitted under applicable law, if a petition is
filed against the other Party for an involuntary proceeding under any applicable bankruptcy or other similar law, and (a) such petition has not been dismissed within sixty (60) days after filing or (b) a court having jurisdiction has
appointed a receiver, liquidator, trustee, or similar official of the other Party for any substantial portion of its property, or ordered the winding up or liquidation of its affairs, in each of (a) and (b), upon delivery of notice of such
termination; or 
 (c)      to the extent permitted under
applicable law, if the other Party commences a voluntary proceeding under applicable bankruptcy or other similar law, has made any general assignment for the benefit of creditors, or has failed generally to pay its debts as they become due, upon
delivery of notice of such termination. 
  

	7.	CONFIDENTIALITY 

 7.1      Confidential Information.    Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the parties,
each party agrees that, during the Term and for five (5) years thereafter, such party (the “Receiving Party”) shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose, other
than as expressly provided for in this Agreement, any information furnished to it by or on behalf of the other party (the “Disclosing Party”) pursuant to this Agreement (collectively, “Confidential
Information”). The Receiving Party may use such Confidential Information only to the extent required to accomplish the purposes of this Agreement. The Receiving Party will use at least the same standard of care as it uses to protect
proprietary or confidential information of its own to ensure that its, and its Affiliates’, employees, agents, consultants and other representatives do not disclose or make any 

  

			
	Biocept Clarient Laboratory Services Agreement	 	Page 3 of 8

 CONFIDENTIAL 

 
 
unauthorized use of the Confidential Information. The Receiving Party will promptly notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Disclosing Party’s
Confidential Information. 

7.2      Exceptions.    Confidential Information
shall not include any information which the Receiving Party can prove by competent evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party, generally known or available; (b) is known
by the Receiving Party at the time of receiving such information, as evidenced by its records; (c) is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and without restriction on disclosure; or (d) is
independently discovered or developed by the Receiving Party, without the use of Confidential Information of the Disclosing Party, as evidenced by the Receiving Party’s written records maintained in the ordinary course of business. 

7.3      Authorized Disclosure.    Each party
may disclose Confidential Information of the other party as expressly permitted by this Agreement, or if and to the extent such disclosure is reasonably necessary in the following instances: 

(a)      enforcing such party’s rights under this Agreement;

 (b)      prosecuting or defending litigation as permitted by
this Agreement; 
 (c)      complying with applicable court
orders or governmental regulations, including any filings with the SEC; 

(d)      disclosure to Affiliates, contractors, employees and consultants
who need to know such information for the development and commercialization of the Assay in accordance with this Agreement, on the condition that any such Third Parties agree to be bound by confidentiality and non-use obligations that are no less
stringent than the terms of this Agreement; and 

(e)      disclosure to Third Parties in connection with due diligence or
similar investigations by such Third Parties, and disclosure to potential Third Party investors in confidential financing documents, provided, in each case, that any such Third Party agrees to be bound by reasonable obligations of confidentiality
and non-use. 
 Notwithstanding the foregoing, in the event a party is required to make a
disclosure of the other party’s Confidential Information pursuant to Section 7.3(b) or Section 7.3(c), it will, except where impracticable, give reasonable advance notice to the other party of such disclosure and use efforts to secure
confidential treatment of such information at least as diligent as such party would use to protect its own confidential information, but in no event less than reasonable efforts. In any event, the parties agree to take all reasonable action to avoid
disclosure of Confidential Information hereunder. 

7.4      Confidentiality of this
Agreement.    Except as otherwise provided in this Section 7, each party agrees not to disclose to any Third Party the terms of this Agreement without the prior written consent of the other party hereto, except that each
party may disclose the terms of this Agreement that are otherwise made public prior to the date of such disclosure or to the extent such disclosure is permitted under Section 7.3. 

  

			
	Biocept Clarient Laboratory Services Agreement	 	Page 4 of 8

 CONFIDENTIAL 

 

7.5      Press Releases; Public
Announcements.    Neither party shall make a press release or public announcement that includes information relating to the Collaboration that has not been previously published without the approval of the other party. At
least five days prior to any such press release or public announcement the party proposing to make such press release or public announcement (the “Publishing Party”) shall provide to the other party a draft copy thereof for
its review and approval. The Publishing Party may not publish such press release or public announcement without obtaining the other party’s prior written approval. In addition, the Publishing Party shall, at the other party’s request,
remove therefrom any Confidential Information of such other party. The contribution of each party shall be noted in all publications or presentations by acknowledgment or co-authorship, whichever is appropriate. 

 

	8.	 Warranties; Limitation of Liability 

8.1      Each Party hereby represents, warrants, and covenants
that:    (i) it is a corporation validly organized under the laws of the state of its incorporation and is authorized to do business to the extent necessary to fulfill its obligations hereunder; (ii) it has the full
right and authority to enter into this Agreement, and no consent or authorization not obtained prior to the Effective Date is necessary to be obtained; (iii) it is not aware of any impediment that would substantially impair its ability to
perform the terms and conditions imposed on it by this Agreement; (iv) it has the legal right and power to fully perform its obligations hereunder; and (v) it has not made nor will it make any commitments to others in conflict with or in
derogation of such rights or this Agreement. 

8.2      EXCEPT AS SPECIFICALLY SET FORTH IN THIS AGREEMENT, NEITHER
PARTY MAKES ANY OTHER EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 

8.3      Limitation of
Liability.    WITHOUT LIMITING THE PARTIES’ OBLIGATIONS UNDER SECTION 9, NEITHER PARTY SHALL BE LIABLE FOR ANY SPECIAL, PUNITIVE, INCIDENTAL, OR CONSEQUENTIAL DAMAGES UNDER THIS AGREEMENT, EVEN IF IT HAS BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES. 
  

	9.	 Indemnification 

9.1      Clarient indemnifies and holds harmless Biocept and its
officers and directors and employees thereof from and against any and all liability, losses, claims, expenses, or damages (including reasonable attorney’s fees) of any kind (a “Liability”) to a third party resulting directly or
indirectly from (i) the negligence or willful misconduct of Clarient, or (ii) breach by Clarient of this Agreement; provided that the foregoing obligation to indemnify and hold harmless Biocept shall not apply to the extent that any
Liability of Biocept (A) was sustained as a result of the negligence or willful misconduct of Biocept or (B) is subject to an obligation of Biocept to indemnify and hold harmless Clarient pursuant to Subsection 9.2. 

9.2      Biocept indemnifies and holds harmless Clarient and its respective officers
and 

  

			
	Biocept Clarient Laboratory Services Agreement	 	Page 5 of 8

 CONFIDENTIAL 

 
 
directors and employees from and against any and all Liabilities to a third party resulting directly or indirectly from (i) negligence or willful misconduct of Biocept, (ii) breach by
Biocept of this Agreement, or (iii) a claim brought by a third party that the performance of the Assay by Biocept infringes the intellectual property rights of such third party; provided that the foregoing obligation to indemnify and hold
harmless Clarient shall not apply to the extent that any Liability of Clarient (A) was sustained as a result of the negligence or willful misconduct of Clarient or (B) is subject to an obligation of Clarient to indemnify, defend and hold
Biocept harmless pursuant to Subsection 9.1. 
 9.3      A
Party seeking indemnification under Subsection 9.1 or 9.2, as applicable, shall promptly notify the other Party of any Liability for which such Party intends to claim such indemnification, and such Party shall cooperate fully with the other Party in
the investigation, conduct, and defense of any Liability covered by this Section 9 and provide full information with respect thereto. 
  

	10.	 GENERAL PROVISIONS 

10.1      Governing Law.    This Agreement and
any disputes, claims, or actions related thereto shall be governed by and construed in accordance with the laws of the State of California, USA, without regard to the conflicts of law provisions thereof. 

10.2      Entire Agreement;
Modification.    This Agreement, including any Exhibits hereto, is both a final expression of the parties’ agreement and a complete and exclusive statement with respect to all of its terms. This Agreement supersedes all
prior and contemporaneous agreements and communications, whether oral, written or otherwise, concerning any and all matters contained herein, including that certain Collaboration Agreement, as amended, dated as of August 17, 2011, by and
between the Parties. This Agreement may only be amended, modified or supplemented in a writing expressly stated for such purpose and signed by the parties to this Agreement. 

10.3      Relationship Between the
Parties.    The parties’ relationship, as established by this Agreement, is solely that of independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship between
the parties. Neither party is a legal representative of the other party, and neither party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other party for any purpose whatsoever.

 10.4      Non-Waiver.    The failure
of a party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in
part, in that instance or in any other instance. Any waiver by a party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such party.

 10.5      Assignment.    Except as
expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either party without the prior written consent of the other party (which consent shall not be unreasonably
withheld); provided, however, that either party may assign this Agreement and its rights and obligations 

  

			
	Biocept Clarient Laboratory Services Agreement	 	Page 6 of 8

 CONFIDENTIAL 

 
 
hereunder without the other party’s consent in connection with the transfer or sale of all or substantially all of the business of such party to which this Agreement relates to a Third
Party, whether by merger, sale of stock, sale of assets or otherwise. The rights and obligations of the parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the parties. Any
assignment not in accordance with this Agreement shall be void. 

10.6      No Third Party Beneficiaries.    This
Agreement is neither expressly nor impliedly made for the benefit of any party other than those executing it. 
 10.7      Severability.    If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable or illegal by a court of competent
jurisdiction, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability or legality of any remaining portions of this Agreement. All remaining portions shall remain in full force and effect as if the original
Agreement had been executed without the invalidated, unenforceable or illegal part. 

10.8      Notices.    Any notice to be given
under this Agreement must be in writing and delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed thereafter by any of the foregoing, to the party to be notified
at its address(es) given below, or at any address such party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earlier of: (a) the date of actual receipt; or
(b) if mailed, five calendar days after the date of postmark. 
 If to Biocept, notices must be addressed to: 

Biocept, Inc. 
 5810 Nancy Ridge Drive, Suite 150 
 San Diego, CA 92121

 Attention: David Hale 

Executive Chairman 
 Telephone: (858) 320-8200 
 Facsimile: (858) 320-8225

 If to Clarient, notices must be addressed to: 

Clarient Diagnostic Services, Inc. 

31 Columbia 
 Aliso Viejo, CA 92656 
 Attention: General Counsel 

Telephone: 949 425-5823 
 Facsimile: 949 425-5863 

10.9      Force Majeure.    Each party shall be
excused from liability for the failure or delay in performance of any obligation under this Agreement by reason of any event beyond such party’s reasonable control, including but not limited to, Acts of God, fire, flood, explosion, earthquake,
or other natural forces, war, civil unrest, any strike or labor disturbance. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the party has
not caused such event(s) to occur. Notice of a party’s failure or delay in performance due to force majeure must be given to the other party within five (5) calendar days after its occurrence. All delivery dates under this Agreement that
have been affected 

  

			
	Biocept Clarient Laboratory Services Agreement	 	Page 7 of 8

 CONFIDENTIAL 

 
 
by force majeure shall be tolled for the duration of such force majeure. In no event shall any party be required to prevent or settle any labor disturbance or dispute. In the event of a force
majeure that persists for thirty (30) days or more, then either party may terminate this Agreement upon written notice to the other party. 
 10.10    Counterparts.    This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with
this writing, shall be deemed one and the same instrument. 
 IN WITNESS WHEREOF, the Parties have executed this
Agreement effective as of the Effective Date. 
  

							
	Biocept:	 	Clarient:
		
	Biocept, Inc.	 	Clarient Diagnostic Services, Inc.
				
	By:	 	/s/ Michael J. Dunn	 	By:	 	/s/ C Eglinton Manner
				
	Name:  	 	Michael J. Dunn	 	Name:  	 	Carrie Eglinton Manner
				
	Title:	 	SVP Corp. Dev.	 	Title:	 	CEO
				
	Date:	 	7/23/13	 	Date:	 	7/29/13

  

			
	Biocept Clarient Laboratory Services Agreement	 	Page 8 of 8EX-10.15

 Exhibit 10.15 

** Text omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment requested under Rule 24b-2 and 17 C.F.R. § 200.80(b)(4). 

MASTER LABORATORY RESEARCH SUPPORT AND SERVICES AGREEMENT 

This Master Laboratory Research Support and Services Agreement (the “Agreement”) is entered into by and
between Biocept, Inc., a California corporation (“Biocept”) and Dana Farber Partners Cancer Care, Inc., a not-for-profit tax-exempt corporation organized under the laws of the Commonwealth of Massachusetts
(“Institution”) for the purpose of establishing the terms and conditions under which Biocept will perform certain laboratory research support services and/or studies or tests (“Research Support”) on samples to be
provided by Institution. Biocept and Institution are referred to here individually as a “Party” and collectively as the “Parties”. 
 WHEREAS, Biocept possesses certain scientific and medical expertise and proprietary technology to be used in providing Research Support services to Institution for one or more clinical research
studies (each a “Study”); 
 WHEREAS, Institution from time to time may seek to obtain
the Research Support and services of Biocept for a Study on the terms and conditions set forth herein; 

WHEREAS, Institution and Biocept desire to provide a full statement of their respective rights, obligations and duties in
connection with the performance of any such laboratory Research Support and services by Biocept; 
 NOW,
THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the parties agree as follows: 
  

	 	1.	 STATEMENT OF WORK (SOW); RESEARCH SUPPORT PERFORMANCE 

1.1 This Agreement sets forth the terms for all Research Support and/or services (“Services”) Biocept
shall provide to Institution, except as otherwise agreed in writing by the Parties. Details regarding such Research Support shall be outlined in a written study plan or protocol (as amended or supplemented, the “Statement of Work”
or “SOW”) applicable to such Research Support and Services to be provided, which shall be drafted and approved by the Parties. Each SOW shall be individually numbered, titled and signed by the Parties, and is incorporated herein by
this reference. Each SOW shall set forth the specific number and type of samples to be tested, and the specific analyses to be performed. SOW BIOCEPT#01, a copy of which has been agreed upon by the Parties, shall apply for purposes of the
initial Study. 
 1.2 This Agreement, together with each individual SOW (including any amendments or
supplements), but separate and apart from any other SOW, shall constitute the entire agreement between the Parties for the performance of any Research Support defined in the applicable SOW. Any changes to a SOW shall be in writing, executed by the
Parties, attached to the original SOW and incorporated therein. 

 1.3 The performance of any Research Support and Services shall be controlled
by the terms and conditions of this Agreement (including any applicable SOW). Any terms and conditions in any purchase order, invoice, acknowledgment, confirmation or other document provided by either Party to the other Party that are different from
or in addition to those set forth in this Agreement are expressly rejected and shall be of no effect, even if signed and returned. In the event of a conflict between the terms and conditions of this Agreement and any SOW, the terms and conditions of
this Agreement shall control. 
 1.4 Biocept shall perform all Research Support and Services in compliance with
the applicable SOW and with Biocept’s standard practices including standards of good laboratory practices. Further, the Research Support and Services shall be performed by qualified personnel in a professional and competent manner, in
compliance with all applicable laws, ordinances, rules regulations and guidelines of the United States Food and Drug Administration (“FDA”) and other applicable regulatory authorities and Biocept shall provide data to Institution in a
format suitable for use by the FDA if so required. Biocept shall at all times during the term of this Agreement and any SOW maintain all licenses as are necessary for the performance of the Research Support and Services. 

1.5 Biocept shall prepare and deliver to Institution, in a timely fashion, all reports and other documentation required
under a SOW. In addition, upon completion of any Research Support and Services, Biocept shall prepare and provide to Institution a final written report describing, in a scientific and detailed manner, its activities in the course of performing the
Research Support and Services and the results obtained therefrom. Institution shall own and have unrestricted right to use the results generated in connection with the performance by Biocept of the Research Support under this Agreement other than
Biocept Technology (defined in Section 10.2). Institution shall have the right to use any information contained in the summary of results and final written report other than Biocept Technology (defined in Section 10.2) for its research,
education, and clinical purposes, for inclusion in grant applications, and as necessary to comply with any federal, state or local government laws or regulations. 
  

	 	2.	 STUDY SAMPLES 

 2.1 Institution shall provide Biocept with sufficient amounts of samples (“Samples”), typically human blood samples, to be tested. Biocept agrees to use the Samples only for the purposes
set out in the SOW. Biocept shall not sell or otherwise distribute Samples to a third party for any purpose. This Agreement and the resulting transfer of Samples constitute a non-exclusive license to use the Samples solely for the research purposes
described in the specific SOW under which the Samples are transferred. Biocept shall not use Samples for any products or processes for profit-making or commercial purposes. Upon termination or expiration of the Research Support and Services under a
specific SOW, Biocept shall either arrange to return to Institution or destroy all unused Samples. 
 2.2 For
each Sample provided to Biocept in connection with Biocept’s performance under the SOW, Institution shall provide to Biocept in writing the associated patient staging data for the patient from whom such Sample was obtained, including, but not
limited to, such 

  
 2 

 
patient’s diagnosis, TNM analysis, the status of such patient’s cancer, biomarker analysis performed on the tumor with results, etc. (collectively, the “Sample
Information”). Institution shall ensure that the informed consent of each patient that is the source of Samples or Sample Information is obtained in compliance with applicable federal, state and local laws, rules and regulations. Biocept
will use, store, and disclose any Samples including (i) any blood, serum, urine, saliva, bone marrow or tissue sample/specimen and (ii) any tangible material isolated therefrom, including but not limited to any DNA, RNA and other
biological substances it receives only in accordance with the uses set forth in the protocol or SOW and informed consent form signed by study subjects and in compliance with applicable law, and in any event will not use, store, or disclose any
individually identifiable health information attached to or contained within the Sample in any manner that would violate the terms of Section 6.4 of this Agreement. 

2.3 The Parties agree that Institution owns the Samples and the transfer of such materials to Biocept under the terms of
this Agreement shall not affect Institution’s ownership interest therein. Institution shall clearly mark and identify all Samples transferred to Biocept. All Samples will be maintained by Biocept so that such materials are readily identifiable.
Further, the transfer of Samples to Biocept gives Biocept no rights in such material other than those specifically set forth in this Agreement. Biocept agrees to use the Samples solely for the Research Support and Services as specified in the SOW
for which such materials are provided hereunder and shall not transfer, deliver or otherwise release such materials to a third party without the express prior written consent of Institution. 

 

	 	3.	 STUDY DIRECTOR 

 3.1 Biocept shall appoint a “Study Director” to be responsible for each SOW. The Study Director shall coordinate performance of the Research Support and Services related to a SOW with a
representative designated by Institution, which representative shall have responsibility for coordinating performance of the SOW for Institution. The Study Director and Institution’s representative shall be named in each SOW. 

 

	 	4.	 COMPLIANCE; RECORDS 

 4.1 Biocept shall perform Research Support and Services in accordance with the current state of the laboratory research art and the applicable SOW. Biocept shall comply with those government regulatory
requirements, if and as specified within the applicable SOW, and as appropriate to the Research Support and Services. If Institution requires any special procedures to be undertaken by Biocept, such procedures shall be reviewed prior to the start of
work and, if accepted, appended to the SOW. 
 4.2 Biocept shall maintain complete and accurate records, in
appropriate detail for regulatory purposes, fully and properly reflecting all tests performed by it and the results thereof, including without limitation, such data and materials as are required to be maintained pursuit to any applicable law,
ordinance, rule or regulation, and any applicable SOW (“Records”). 

  
 3 

 4.3 Biocept shall maintain the Records for two (2) years or such other
longer amount of time as is required by any law, ordinance, rule or regulation, or the applicable SOW. Upon Institution’s request, and at Institution’s expense, Biocept shall deliver to Institution all original Records, or if requested by
Institution, certified or authenticated complete legible copies of such Records. 
 4.4 Access to all Records,
for inspection and copying, shall be made available by Biocept to Institution upon reasonable prior written notice to Biocept during normal business hours; provided, however, that Biocept shall not be obligated to provide Institution with access to
information not directly related to the Research Support or, except as expressly set forth in a SOW, access to any Biocept Technology (defined in Section 10.2) or any Confidential Information (defined below) of Biocept, and that Biocept may
require that Institution’s representatives conducting any such examination or inspection first execute a non-disclosure agreement. 
  

	 	5.	 LABORATORY VISITS 

 5.1 Institution’s representative(s) shall have the right to conduct inspections, audits and investigations of Biocept’s facilities, equipment, record-keeping procedures and records, and to
discuss the same with appropriate representatives of Biocept from time to time to determine that any Research Support is being conducted in accordance with this Agreement. Institution shall provide reasonable prior written notice to Biocept, and may
at reasonable times and with reasonable frequency, during normal business hours, observe the progress of a SOW and its associated Research Support and Services but in a manner not to unreasonably disturb or impede progress on such SOW. Biocept shall
assist Institution in scheduling such visits, but reserves the right to schedule such visits as may be necessary so as not to compromise confidential or proprietary information of other Biocept customers who may have studies ongoing at Biocept at
the time of any requested visit. Biocept shall promptly rectify any material noncompliance with the terms of the Agreement, including applicable protocol specifications and standards of good laboratory practices discovered during such inspections,
audits and investigations of which Biocept is notified. Biocept shall submit to all inquiries, audits and inspections by the FDA and other applicable regulatory authorities relating specifically to the Research Support and Services. To the extent
permitted by applicable law, Biocept shall promptly notify Institution upon receipt of notice of any inspection by the FDA or any applicable regulatory authorities relating specifically to the Research Support and Services provided hereunder, and
Biocept shall promptly notify Institution of any findings of such regulatory authorities. 
  

	 	6.	 CONFIDENTIAL INFORMATION 

 6.1 “Confidential Information” of a Party shall mean all information disclosed or made available by such Party (the “Disclosing Party”) to the other Party (the
“Receiving Party”) in connection with this Agreement. Confidential Information of Biocept shall include, without limitation, all Biocept Technology (defined in Section 10.2) disclosed or made available by Biocept to
Institution. Confidential Information of Institution shall include, without limitation, the Samples, Sample Information, and, notwithstanding the first sentence of this Section 6.1, all results. Confidential Information shall not include
information that the Receiving Party can 

  
 4 

 
demonstrate by competent evidence: (a) is now, or hereafter becomes, through no breach of this Agreement by the Receiving Party, generally known or available; (b) is known by the
Receiving Party at the time of receiving such information, as evidenced by its pre-existing written records; (c) is hereafter furnished to the Receiving Party by a third party, as a matter of right and
without restriction on disclosure; or (d) is hereafter independently developed by the Receiving Party without reference to or reliance upon Confidential Information and without any breach of this Agreement as evidenced by written records.

 6.2 Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the
Parties, the obligations of confidentiality survive for seven (7) years beyond the later of (i) expiration or earlier termination of this Agreement or (ii) the expiration or earlier termination of the SOW under which the Confidential
Information was disclosed. The Receiving Party shall: (i) maintain the confidentiality of the Confidential Information; (ii) use Confidential Information only for the purposes expressly contemplated by this Agreement, or a SOW;
(iii) treat Confidential Information as it would its own proprietary information, which in no event shall be less than a reasonable standard of care; (iv) take all reasonable precautions to prevent the disclosure of Confidential
Information to a third party, and (v) disclose Confidential Information only to those employees who have a need to know such Confidential Information for the purposes expressly contemplated by this Agreement or a SOW, and who are subject to
obligations to confidentiality substantially similar to those set forth herein. Notwithstanding the foregoing, the Receiving Party may disclose Confidential Information to the extent required by law, rule, regulation, government requirement or court
order, provided that the Receiving Party shall provide reasonable prior written notice to the Disclosing Party of such required disclosure and, at the Disclosing Party’s request and expense, shall cooperate with the Disclosing Party’s
efforts to contest such requirement, or to obtain a protective order covering, or other confidential treatment of, the Confidential Information required to be disclosed. 

6.3 Institution shall comply in all material respects with all applicable federal, state and local laws and regulations
regarding the privacy of individually identifiable health information (including its collection, use, storage, and disclosure), including, but not limited to, the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and
the regulations promulgated thereunder, as may be amended from time to time. Biocept agrees to use, store, and disclose individually identifiable health information contained or provided with the Samples only for the purpose of the Research Support
and Services, and for the purpose of complying with applicable law. Biocept will use all reasonable efforts to protect the privacy and security of any individually identifiable health information contained or provided with the Samples and will
require its business partners to do so also. Biocept will not contact any patients whose Samples they have been are provided, unless permitted by the informed consent form. No other provision in this Agreement shall be construed to override the
provisions of this Section 6.4 
  

	 	7.	 REPRESENTATIONS, WARRANTIES AND DISCLAIMERS 

7.1 Each Party represents and warrants to the other the other Party that (i) it is duly organized, validly existing
and in good standing under the laws of their respective state of 

  
 5 

 
incorporation, organization or formation, (ii) it has full corporate or entity power and authority to execute, deliver and perform this Agreement, (iii) this Agreement is enforceable
against it in accordance with its terms, and (iv) this Agreement does not conflict with, violate or constitute a breach or default under any other agreement of a material nature or amount to which it is a party or to which it or its assets are
subject. 
 7.2 Except as expressly set forth in this Agreement, THE CONFIDENTIAL INFORMATION, SAMPLES,
MATERIALS, WORK PRODUCT AND TECHNOLOGY MADE AVAILABLE BY EACH PARTY TO THE OTHER PARTY HEREUNDER ARE BEING SUPPLIED “AS IS’, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND EACH PARTY
HEREBY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF TITLE, MERCHANTABILITY, NON-INFRINGEMENT, SAFETY, OR FITNESS FOR A PARTICULAR PURPOSE. THE SAMPLES HAVE NOT BEEN ANALYZED OR TESTED BY
INSTITUTION AND MAY, THEREFORE, CONTAIN VIRUSES, BACTERIA OR OTHER POTENTIALLY DANGEROUS COMPONENTS. BIOCEPT ACKNOWLEDGES AND ACCEPTS THE RISKS OF SUCH VIRUSES, BACTERIA OR OTHER POTENTIALLY DANGEROUS COMPONENTS. 

 

	 	8.	 INDEMNIFICATION 

 8.1 Each Party shall be solely responsible for such Party’s (including its employees, agents and representatives) acts of negligence and/or reckless acts or omissions in the performance of their
duties hereunder, and shall be financially and legally responsible for all liabilities, costs, damages, expenses and attorney fees resulting from, or attributable to any and all such acts or omissions. Neither Party shall have any obligation to
indemnify the other Party and/or their agents, employees and representatives. 
 8.2 Each Party shall maintain
general liability and malpractice insurance (either on an indemnity or self-insured basis) in an amount not less than $1,000,000 per occurrence, $2,000,000 aggregate, and $2,000,000.00 per occurrence, $2,000,000.00 aggregate, respectively.

 8.3 Limitation of Liability. IN NO EVENT SHALL EITHER PARTY BE ENTITLED TO RECOVER FROM THE OTHER
PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING, WITHOUT LIMITATION, LOST PROFITS AND THE COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES, IN CONNECTION WITH THIS AGREEMENT. 

 

	 	9.	 USE OF NAMES 

 9.1 Except as is required by law or for disclosure by Institution of Biocept’s support for a Study in publications, neither Party to this Agreement shall use the name of the other Party or of any
staff member, employee, student, or agent of the other Party or any adaptation, acronym or name by which the other Party is commonly known, in any advertising, promotional or sales literature or in any publicity without the prior written approval of
the Party or individual whose name is to be used. 

  
 6 

	10.	 INVENTIONS AND PATENTS 

 10.1 Institution will own and have unrestricted free right to use for all purposes the data and information generated or created for Institution in connection with the performance by Biocept of Research
Support and Services under this Agreement or a SOW, other than Biocept Technology (defined in Section 10.2). Biocept shall provide notice to Institution of all inventions, technology and discoveries conceived, identified, developed and/or
reduced to practice during the course of, and as a direct result of performing, any Research Support and Services or a SOW performed under this Agreement (each, a “Institution Invention”), within sixty (60) days of becoming
aware of such Institution Invention; provided, however, that Institution Inventions shall exclude Biocept Technology, and Biocept shall have no obligation to disclose any Biocept Technology to Institution except as expressly contemplated by a
SOW. All Institution Inventions shall be assigned to Institution by Biocept at Institution’s request, provided Institution requests such assignment within six (6) months of notification of such invention or discovery. Biocept shall provide
Institution with reasonable technical assistance as Institution may request and at Institution’s cost to obtain patents on Institution Inventions. Biocept shall ensure that each of its employees, agents, consultants and subcontractors
performing any part of the Research Support and Services is contractually obligated to assign all Institution Inventions to Biocept so that Biocept can comply with its obligations under this Section 10.1. Institution hereby grants to Biocept a
perpetual, irrevocable, non-exclusive worldwide, royalty-free, fully paid license to use Institution Inventions for its internal research purposes, and otherwise in compliance with Section 6. Neither anything contained herein nor the delivery
of any of the Samples or Confidential Information to Biocept shall be deemed to grant to Biocept any right or licenses under any patents or patent applications or under any know-how, technology or inventions of Institution. 

10.2 Notwithstanding anything to the contrary in this Agreement, all discoveries and inventions that are conceived or
made by Biocept in the course of performing any Research Support and Services or a SOW that relate to microfluidic devices, rare cell capture and analysis technology, and related inventions, processes, know-how, trade secrets, computer software
including image analysis and other methodological innovations, whether developed before or after the Effective Date of a SOW (collectively, “Biocept Technology”), shall be the sole and exclusive confidential property of Biocept.

 10.3 It is expressly agreed that neither Party transfers by operation of this Agreement to the other Party
any patent right, copyright, or other proprietary right either Party owns as of the Effective Date, except as expressly set forth in this Agreement. 
  

	11.	 PUBLICATION OF DATA 

 11.1 By Institution. Institution shall list Biocept’s name, and individual Biocept personnel as authors as appropriate, on any scientific manuscript or abstract that is submitted for
publication or presentation that includes information that has been either directly or indirectly 

  
 7 

 
derived from the Research Support and Services on the Samples and related to the specific SOW under which the Samples were provided and the Research Support and Services were performed under this
Agreement and SOW. Biocept shall be notified of such planned inclusion of its, and its personnel’s, name on scientific manuscripts or abstracts, provide permission for such inclusion, and be permitted to review and comment upon any publication
or abstract on which its name or personnel are listed prior to submission. 
 11.2 By Biocept. In
compliance with Section 6, Biocept shall not undertake publication of the results of any Research Support and Service without first receiving written permission from Institution. Publication of material relating to Biocept Technology, products
or services shall not identify Institution or contain data encompassing Confidential Information belonging to Institution or derived from Samples provided by Institution without first receiving written permission from Institution. 

 

	12.	 TERM AND TERMINATION 

 12.1 Term. The term of this Agreement (the “Term”) shall commence on the Effective Date and, unless sooner terminated by mutual agreement or pursuant to any other provision of this
Agreement, shall terminate five (5) years from the Effective Date. 
 12.2 Termination of Agreement by
Either Party. Either Party may terminate this Agreement for any material breach by the other Party, providing that the terminating Party gives the breaching Party written notice of such breach, and the breach remains uncured after the expiration
of thirty (30) days after such written notice was given. In addition, either Party, in its sole discretion, may elect to terminate this Agreement by giving at least thirty (30) days advance written notice thereof to the other Party;
provided, however, that any SOW ongoing at such time shall be completed pursuant to the terms of this Agreement as if otherwise in effect. A termination of a particular SOW by either Party pursuant to the provisions of Section 12.3 or
Section 12.4 below shall not, by itself, have the effect of or be deemed a termination of this Agreement in its entirety. 
 12.3 Termination of a SOW by Institution. Institution may, in its sole discretion, elect to terminate a SOW being performed under this Agreement by providing written notice thereof to Biocept,
whereupon the following shall occur: 
 a) Biocept shall terminate the work as soon as is reasonably possible,
and in any event within ten (10) days of receipt of the notice; and 
 b) Biocept shall invoice Institution
for, and Institution shall promptly pay, all charges up to the effective date of termination, and any Research Support and Services performed within ten (10) days of receipt of notice, such work intended to efficiently terminate the SOW.

 12.4 Termination of a SOW by Biocept. In the event of non-payment by Institution of any amount due and
owing to Biocept pursuant to the Cost Schedule for a SOW as appropriately invoiced, and upon written notice thereof to Institution, Biocept may (in its sole discretion and in addition to any other remedies that Biocept may have at law or in equity)
terminate such SOW in 

  
 8 

 
any reasonable manner (and stop work on other Research Support and Services being performed for Institution, if any, without any adverse effect on Biocept’s rights in connection with such
Research Support and Services or SOW). 
 12.5 Effect of Termination or Expiration. Termination or
expiration of this Agreement for any reason shall not relieve the Parties of any obligation accruing prior thereto and shall be without prejudice to the rights and remedies of either Party with respect to any antecedent breach of any of the
provisions of this Agreement. In the event of termination of this Agreement prior to the completion of Research Support specified in any SOW, Biocept shall be paid for all work completed through the effective date of termination in accordance with
this Agreement, and such SOW(s), including reasonable and documented out-of-pocket expenses, and unless this Agreement is terminated by Biocept for convenience or Institution for default, any non-cancellable commitments incurred by Biocept in
accordance with this Agreement and such SOW. Except as set forth in the preceding sentence, Biocept shall promptly refund to Institution any prepaid amounts not earned by Biocept prior to the effective date of such termination. Sections 2, 4,
5, 8, 6.4, 8, 9, 10, 11 and 15.2 of this Agreement shall survive expiration or any termination hereof. 
  

	 	13.	 NOTICES 

 13.1 All notices given under this Agreement shall be in writing and shall be delivered personally, sent by facsimile transmission (receipt confirmed), overnight express courier (such as FedEx) or
certified mail, return receipt requested, to the Parties at the addresses set forth on the signature page of this Agreement, or such other addresses as the Parties may designate in writing. A notice shall be deemed delivered and effective
(i) if sent by facsimile transmission (receipt confirmed), on the business day following the date such facsimile transmission was sent and confirmed, (ii) if sent by overnight express courier, on the business day delivery is confirmed by
signature of the receiving party, and (iii) if sent by certified mail, on the second business day following mailing. 
  

	 	14.	 PAYMENTS TO BIOCEPT PURSUANT TO COST SCHEDULE 

14.1 Institution and Biocept shall agree upon a budget for all Research Support and Services to be provided under a SOW
by Biocept, which shall specify the fees for individual Samples or a Study. The schedule will be attached to the individual SOW (the “Cost Schedule”), which is hereby incorporated in this Agreement by this reference. Costs specified in the
SOW are estimated prior to commencement of a Study, and Institution shall pay Biocept the amounts indicated there, as Research Support and Services are provided. The aggregate fees payable by Institution to Biocept for Research Support and Services
shall not exceed the budget for such Research Support as in the SOW, regardless of the number of Samples or transactions processed, unless Institution shall expressly consent in writing to an increase in such budget, although Biocept shall only be
responsible for testing the number of Samples indicated in the SOW without such written modification. 

  
 9 

 14.2 Once each calendar month, Biocept shall submit to Institution a single
written invoice detailing amounts due to Biocept for performance of Research Support and Services as detailed in each SOW. 
 14.3 Institution shall pay Biocept invoiced amounts within forty-five (45) days of receipt of each invoice. Notwithstanding the foregoing, Biocept shall not be entitled to payment for invoiced
amounts in excess of the costs for Research Support and Services specified in a SOW unless Biocept has obtained prior written authorization from Institution for such excess cost. Material amendments, deletions or additions to the SOW requested by
Institution or by Biocept shall be the subject of separate additional cost estimates and require Institution’s and Biocept’s written acceptance thereto. 

14.4 If any Research Support and Services are improperly performed, or Samples are unusable due to a delay caused by
Biocept or as the result of an error, omission, or other wrongdoing or negligence by Biocept in performance of the Research Support and Services, Biocept will re-run the affected Service or portion of the work as promptly as possible at no cost to
Institution, provided that Institution sends replacement Samples for testing. 
 14.5 Test results will be
forwarded to Institution or its designee no later than fourteen (14) days after delivery of a Sample to Biocept, unless otherwise agreed by Biocept. 
 14.6 Biocept will not employ subcontractors to perform the laboratory services contemplated hereby without Institution’s prior written consent. 

 

	 	15.	 MISCELLANEOUS PROVISIONS 

 15.1 Assignment. Neither this Agreement nor any rights or obligations hereunder may be assigned by either Party without the prior written consent of the other Party (which consent shall not be
unreasonably withheld); provided, however, that either Party may assign this Agreement and its rights and obligations hereunder without the other Party’s consent in connection with the transfer or sale to a third party of all or substantially
all of the business of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the
successors and permitted assigns of the Parties, and the name of a Party appearing herein will be deemed to include the name of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this section. Any
assignment not in accordance with this Agreement shall be void. 
 15.2 Applicable Law. The Parties agree
to remain silent on applicable law. 
 15.3 Independent Contractor. Nothing herein shall create any
association, partnership, joint venture, fiduciary duty or the relation of principal and agent between the Parties hereto, it being understood that each Party is acting as an independent contractor, and neither Party shall have the authority to bind
the other or the other’s representatives in any way. 

  
 10 

 15.5 Remedies. The Parties acknowledge that breach of this Agreement
or use of information provided by a Party contrary to the provisions of this Agreement may cause irreparable harm for which damages at law may not be an adequate remedy. Either Party may seek injunctive or other equitable relief from any court of
competent jurisdiction as may be necessary to protect the rights or property of that Party 
 15.6
Force Majeure. Except for the obligation to pay money, a Party shall be excused from performing its obligations under this Agreement if its performance is delayed or prevented by any cause beyond such Party’s reasonable control,
including, but not limited to, fire, flood, storm, tornado, earthquake, civil commotion, legal prohibition, strike, disease, Act of God, explosion, war, hostilities, vandalism or any catastrophe (a “Force Majeure Event”).
Performance shall be excused only to the extent of and during the continuance of the Force Majeure Event. Any deadline or time for performance specified in the SOW which falls due during or subsequent to the occurrence of a Force Majeure Event shall
be automatically extended for a period of time equal to the period of such Force Majeure Event. Any Party claiming disability of performance due to a Force Majeure Event shall promptly notify the other Party in writing of such Force Majeure Event.
If Biocept is rendered practicably incapable of completing a Study or SOW within the time schedule required by Institution as a result of a Force Majeure Event, Biocept shall endeavor to conclude such Study or SOW in such a manner as to secure all
possible data and information relevant to the objective of such Study or SOW without engaging in substantial further work. Under such circumstances, neither Party shall have any claims against the other except with respect to Institution’s
liability to pay all charges accrued or earned up to the date of such termination (on a prorated basis, if appropriate). 
 15.7 Entire Agreement; Amendments; Severability; Headings. This Agreement represents the entire understanding and agreement between Biocept and Institution with respect to the subject matter
hereof, and shall control over any previous or contemporaneous agreements, oral or written, between Institution and Biocept. Changes and additional provisions to this Agreement shall be binding on the Parties only if mutually agreed to, laid down in
writing and signed effectively by the Parties. If any one or more of the provisions of this Agreement is held to be invalid, illegal or unenforceable to any extent in any context, this Agreement shall nevertheless be enforced to the fullest extent
allowed by law, and the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. The headings of the paragraphs herein are for convenience only, and they shall not be of any effect in
construing the contents of the respective paragraphs. 
 15.8 Neutral Construction. Each Party
acknowledges that in the negotiation and drafting of this Agreement they have been represented by and have relied upon the advice of counsel of their choice. The Parties affirm that they and their counsel have had a substantial role in such
negotiation and drafting and, therefore, the Parties agree that this Agreement shall be deemed to have been drafted by all the Parties hereto and the rule of construction to the effect that any contract ambiguities are to be resolved against the
drafting party shall not be employed in the interpretation of this Agreement or any exhibit hereto. 
 15.9
Waiver. No delay on the part of either Party hereto in exercising any power or right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any 

  
 11 

 
power or right hereunder preclude other or further exercise thereof or the exercise of any other power or right. No waiver of this Agreement or any provision hereof shall be enforceable against
any Party hereto unless in writing, signed by the Party against whom such waiver is claimed, and shall be limited solely to the one event. Each Party’s rights and remedies hereunder are cumulative and not exclusive. 

15.10 Third-Party Beneficiaries. The Parties agree that there are no third-party beneficiaries of any kind to this
Agreement. 
 15.11 Signatures; Counterparts. Each Party agrees that a facsimile of its signature
printed by a receiving fax machine or an electronic copy of its signature stored in a PDF software application format shall be regarded as an original signature. Each Party further agrees that this Agreement may be executed in any number of
counterparts, each of which shall be effective upon delivery and thereafter shall be deemed an original, and all of which shall be taken to be one and the same instrument. 
 IN WITNESS WHEREOF, INTENDING TO BE LEGALLY BOUND, the Parties have executed and delivered this Agreement by their duly authorized representatives, to be effective as of July 9, 2012. 

Signatures on the following page 

  
 12 

							
	 Biocept, Inc.
 5810 Nancy Ridge Drive, Suite 150
 San Diego, California 92121

Phone: (858) 320-8200
 Fax: (858) 320-
	  	 Dana Farber Partners Cancer Care, Inc.

450 Brookline Avenue, BP319
 Boston, Massachusetts 02115
 Phone: 617-582-7717

Fax: 617-632-4452

				
	 By:
	 	 /s/ Michael J. Dunn
	  	 By:
	  	 /s/ Moira Hayes Waligory

	 Name:
	 	 Michael J. Dunn
	  	 Name:
	  	 Moira Hayes Waligory, RN, JD

	 Title:
	 	 SVP of Corporate Development
	  	 Title:
	  	 Clin. Res. Contracts Assoc.

  
 13 

 Statement of Work – Sample 

This Statement of Work (“SOW”), dated and effective [Month, Date, Year], submitted in connection with the Master Laboratory Services Agreement
by and between Biocept and Dana Farber Partners Cancer Care, Inc. dated July 9, (“Agreement”), is hereby agreed to by the Parties. 

Pursuant to Section 2 of the Agreement, this SOW (including any attachments hereto) shall be governed by the terms and conditions of the Agreement
and, if applicable, any modifications to the Agreement agreed to by the Parties and set forth in this SOW under the section below, entitled “Modifications to Agreement.” Any modifications shall apply only to this SOW, and not to any
previous or subsequent SOWs, unless expressly stated otherwise in such other SOW. 
 Modifications to Agreement 

INSERT MODIFICATIONS: 
 Study 

Biocept shall conduct the following testing for Dana Farber Partners Cancer Care, Inc.: 

 

			
	Study Title and Scope	  	Total Cost
	 XXX
	  	XXX

 Cost Schedule/Budget 
 Dana Farber Partners Cancer Care, Inc. shall pay Biocept for the SOW as follows:             

Study Directors 
 Biocept: 

Dana Farber Partners Cancer Care, Inc.: 
 Any
invoices provided pursuant to this SOW shall be submitted to Dana Farber Partners Cancer Care, Inc., 450 Brookline Avenue, BP317, Boston, MA 02215 in accordance with the terms and conditions set forth in the Agreement and directed to the attention
of: James Huse. 
  
  

			
	 Biocept, Inc.
	  	 Dana Farber Partners Cancer Care, Inc.

		
	 By: 
                                         
                           
	  	By: 
                                         
                           

  
 14 

			
	 Name: 
                                         
                      
	  	 Name: 
                                         
                      

		
	 Title: 
                                         
                         
	  	 Title: 
                                         
                         

		
	 Date: 
                                         
                         
	  	 Date: 
                                         
                         

  
 15 

 Statement of Work – Biocept #01 

This Statement of Work (“SOW”), dated and effective June 20, 2012, submitted in connection with the Master Laboratory Services
Agreement by and between Biocept and Dana Farber Partners Cancer Care, Inc. dated July 9, 2012 (“Agreement”), is hereby agreed to by the Parties. 
 Pursuant to Section 1 of the Agreement, this SOW (including any attachments hereto) shall be governed by the terms and conditions of the Agreement and, if applicable, any modifications to the Agreement
agreed to by the Parties and set forth in this SOW under the section below, entitled “Modifications to Agreement.” Any modifications shall apply only to this SOW, and not to any previous or subsequent SOWs, unless expressly stated
otherwise in such other SOW. 
 Modifications to Agreement 
 Study 
 Biocept shall conduct the following testing for Dana Farber Partners Cancer Care,
Inc: 
  

			
	Study Title and Scope	  	Total Cost
	 Phase 1 study of metastatic breast
cancer patients who are HER2- by tumor, HER2+ by CTC, testing treatment with Herceptin (see attached Appendix)
	  	Est. up to
[**]

 Cost Schedule/Budget 
 Dana Farber Partners Cancer Care, Inc. shall pay Biocept for the SOW as follows: 

[**] per Sample tested, with up to 250 patients screened to identify 35 study patients, who will each be tested 3 times during the course
of the study. 
 Study Directors 

Biocept: Farideh Bischoff, Ph.D. Dana Farber Partners Cancer Care, Inc.: Ian Krop, MD 

Any invoices provided pursuant to this SOW shall be submitted to Dana Farber Partners Cancer Care, Inc., 450 Brookline Avenue, BP317,
Boston, MA 02215 in accordance with the terms and conditions set forth in the Agreement and directed to the attention of: James Huse 
  

			
	 Biocept, Inc.
	  	 Dana Farber Partners Cancer Care, Inc.

		
	 By: 
                                         
                           
	  	By: 
                                         
                           
		
	 Name: 
                                         
                      
	  	 Name: 
                                         
                      

		
	 Title: 
                                         
                         
	  	 Title: 
                                         
                         

		
	 Date: 
                                         
                         
	  	 Date: 
                                         
                         

 ** Confidential treatment requested 

  
 16 

 Appendix 
 Sample Collection 
 Blood samples (“Samples”) are to be collected
during the screening evaluation. Samples may be drawn [**] (unless prior arrangements to receive the Sample have been made). Samples are to be collected in preservative tubes provided by Biocept Inc (7.5 mL). One tube is needed; however,
the goal is [**]. Gently invert each tube 8 times to prevent clotting immediately after filling the tube. Label tube with sample identifier / number, protocol number, submitting investigator and date of collection. Ensure the
peripheral blood collection occurs prior to the administration of IV therapy. If the patient is being treated with radiation or had a recent CT scan, it is recommended to wait at least 3 days after administration before drawing a blood
sample.
 Sample storage and transport 
  

The blood sample can be transported and stored at room temperature (15-30° C) until processing. Do not refrigerate or freeze the Sample. Samples must be processed at Biocept
Laboratories within [**] hours of collection, but best results are obtained if the Sample is processed as soon as possible. Do not submit clotted Samples. Samples should be shipped by same day courier or overnight parcel. 

Testing and notification

CTCs will be measured at Biocept Laboratories Inc in a CLIA-approved laboratory. As outlined in Mayer et al, Cancer Genetics, 2011, CTCs
will be captured using an antibody cocktail directed to ten different tumor-associated cell surface antigens, further labeled with a biotin-conjugated secondary antibody, and captured in a proprietary streptavidin-derivatized microchannel. FISH
assays for HER2 and EGFR will be performed in the microchannel using Abbott probes, and will be evaluated and scored by cytotechnicians at high power under the microscope. CTCs will be analyzed per Sample and Samples will be considered amplified if
the ratio of HER2 copy number to CEP17 copy number is 32.0. If a Sample is FISH positive by this definition, the patient’s treating physician will be notified that the patient is eligible for
this study. 
 ** Confidential treatment requested 

  
 17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]